Icon

Epiduo - (0.1%, 2.5%; Gel, topical)

Adapalene and Benzoyl Peroxide Galderma
0.1%, 2.5%; Gel, topical
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
Less Than 5
Less Than 5
Indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Yes
******* ** *** *** *** *** **** ** *********** ******* ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (*** **, ****), ‘*** (**** **, ****) *** ************ *********. ****** **** ******** ******** ***** *** **** ** **** ******* ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (*** **, ****), ‘*** (**** **, ****) *** *** ************ *********. ****** ******** ******* *** **** ******** *** ******* ** ***, ********** **** ******* *********. ***** *** ********** **** ******* *** *** *** ******* ***** *** ***** ** ********** *** *** *****. ******** ***** * **** ** ** **** ******* ** ****** *** *** *********** *********. **** *** ********* *** ******** ****** *** *** ******* ** ***** ****. * **** ***** *** ********** ** ******** ****** **** ***** * **** ** **** ****** *** *** *** ************ *********. ****, *** **** ******* **** *** ********* **** ***** ** ********* *** *****. **** ******** ******* ****** ** ** ** ***, **** **** ***-**** ***********.
Epiduo Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
*** ****** ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
******** ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** *** *, **** ******* ******** ******** ** *** **, ****
*** ****** ** \ ** *** **, **** ******* ******** *** ****** *** ****
******** ** \ ** *** *, **** ******* ******** ******** ** *** *, ****
  1. *** **, **** : ******* ******** ******** ***** *** **** ** *********** *** ****** **** ******* '***, '***, '***, '***, '*** *** '***.
  2. **** *, **** : ******** **** ******* ** ******** ******** ***** ** *****.
  3. **** **, **** : ****** ******** ******** ***** *** **** ** *********** ******* '***, '*** *** '***.
  4. **** **, **** : ******** **** ****** ** ******** ******** ** *****.
  5. *** **, **** : ******** *** *** *******; ******* ***** *** *** *****. ****** ******** *** **** ** *** ** ****** ******** *******.
  6. *** **, **** : ******** ******** ******** ***** *** **** ** *** ****** **** ******* ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (*** **, ****), ‘*** (**** **, ****).
  7. *** *, **** : ******** ***** * **** ******* ******** ** ******** ***** ** ******** ******** ** *****.
  8. *** **, **** : ********** **** ******* *** ********* ***** *** ***** ** ********* *** *** *****.
  9. *** **, **** : **** ******** ********* **** ** **** ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (*** **, ****), ‘*** (**** **, ****).
  10. *** **, **** : ******** ***** * **** ******* **** ** **** ***** * **** ** ** ******* ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (**** **, ****), ‘*** (*** **, ****), ‘*** (**** **, ****).
  11. *** **, **** : ******** **** **** ** ** ** ******** ******** ** *****.
  12. *** **, **** : **** ******* **** *** ****** **** ***** ** ********* *** *****.
  13. *** **, **** : **** (*******) ******** ******* ****** ** *** ** *** **** ******* ** *** **** ***********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.